# Chinese guidelines on response assessment and minimal residual disease monitoring in multiple myeloma (2024)

## TL;DR

This paper presents Chinese guidelines for evaluating treatment response and monitoring minimal residual disease in multiple myeloma.

## Contribution

The novelty lies in providing a unified, comprehensive guideline tailored for Chinese clinical practice in multiple myeloma assessment.

## Key findings

- Multiple myeloma response assessment is complex and relies on M protein levels, bone marrow plasma cells, and imaging.
- Minimal residual disease detection reveals deeper remission and has gained clinical consensus.
- The guidelines aim to standardize evaluation and improve treatment guidance in China.

## Abstract

在多发性骨髓瘤（MM）治疗过程中，应用统一的标准对疗效进行评价对于指导治疗、判断预后及解读不同研究结果非常重要。因为疾病本身的特性，MM的疗效判断较其他肿瘤更为复杂，主要基于血、尿单克隆免疫球蛋白（M蛋白）的测定，结合骨髓中浆细胞数量及全身影像学。近年来，随着新药的不断涌现，MM疗效显著提高，微小残留病检测能够显示更深层次的缓解，其临床意义目前已取得广泛共识。在此基础上，中国临床肿瘤学会（CSCO）骨髓瘤专家委员会和中国抗癌协会（CACA）血液肿瘤专业委员会组织相关专家制定了本指南，旨在为MM的疗效评估提供全面参考。